Abstract
Vitiligo is a common disorder of skin pigmentation resulting from autoimmune destruction of melanocytes. A variety of topical and systemic treatment options have been tried with varying success. Here we describe the case of a man with refractory vitiligo successfully treated with topical crisaborole ointment. Crisaborole ointment is a topical phosphodiesterase (PDE)-4 inhibitor recently FDA-approved for the treatment of atopic dermatitis. Previous literature has discussed the possible role of systemic PDE-4 inhibitors in vitiligo; herein, we discuss the ability of topical crisaborole to accelerate repigmentation in treatment-resistant vitiligo.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 111-113 |
| Number of pages | 3 |
| Journal | SKIN: Journal of Cutaneous Medicine |
| Volume | 3 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 11 2019 |
Keywords
- PDE-4 inhibitor
- Vitiligo
- crisaborole
ASJC Scopus subject areas
- Dermatology